InformedDNA

InformedDNA is a genomics services and technology company that provides genetic counseling, genetic testing utilization management, precision health programs, payment integrity, and clinical trial recruitment support to payors, life sciences companies, health systems, providers, laboratories, and employer groups across the United States. Founded in 2007, it describes itself as the first telehealth genetic counseling company in the nation and says it has provided genetic counseling to more than 200,000 patients.

Its core telegenetic counseling service gives nationwide telehealth access to board-certified, licensed genetic counselors covering oncology, cardiology, neurology, pediatric and adult genetics, pharmacogenomics, ophthalmology, reproductive and maternal-fetal medicine, mental health, and whole genome/exome sequencing. The workflow spans patient referral (with contact within two business days and expedited same-day handling for urgent cases), pre-test counseling and risk assessment based on personal and family health history, test ordering and coordination with major laboratories, and post-test consultation with a personalized summary report delivered to the patient and referring provider. The company states it has no laboratory affiliations, which it presents as removing conflicts of interest in test selection.

On the payor side, InformedDNA offers medical policy development, prior authorization and decision-support automation intended to reduce spending on inappropriate genetic tests and downstream procedures. Its DNAimpact platform is a precision health program for health plan members or employees that performs population risk stratification, personalized screening protocols, education, testing, genetic counseling, and management recommendations. Additional services include clinical trial participant recruitment, screening, and site auditing for drug developers.

Founding story

The company was founded in 2007 and was co-founded by David Patrick Nixon, who serves as Executive Chairman, and Rebecca Sutphen, MD, FACMGG, who serves as Chief Medical Officer; both also sit on the board of directors.

Business model

InformedDNA sells genomics services and technology to organizations rather than primarily direct-to-consumer: payors and health plans, health systems, hospitals, providers, laboratories, employer groups, pharmaceutical companies and CROs, and other risk-bearing organizations. Offerings are packaged as named programs and services — DNAimpact, DNAassist, genetic counseling, payment integrity, clinical trial recruitment, and genetic testing utilization management — positioned around cost management, utilization control, and clinical decision support. The company has achieved in-network status with state, regional, and national health plans, which it says reduces patient cost of care and handles billing and reimbursement administration on clients' behalf.

Revenue is derived from services and platform offerings sold to institutional clients — genetic counseling delivered via telehealth (with in-network health plan billing and reimbursement handled by the company), genetic testing utilization management and medical policy services, payment integrity, precision health programs for members and employees, and clinical trial recruitment, screening, and site auditing services for pharmaceutical sponsors and CROs.

Traction

InformedDNA reports genetic counseling services delivered to more than 200,000 patients since its 2007 founding and a Net Promoter Score of 72 for its telehealth appointments. It reports in-network status with state, regional, and national health plans. Third-party data as of July 2026 estimates annual revenue of $25M-$50M and approximately 87 employees, with a listed range of 51-200.

Latest developments

In March 2025 InformedDNA acquired Coriell Life Sciences, a pharmacogenomics and clinical-decision support company, adding to its September 2023 acquisition of gWell Health. In December 2024 it launched a precision medicine program for obesity with Phenomix Sciences, following an October 2024 integration of Phenomix's MyPhenome genetic obesity test with the DNAimpact platform. In December 2025 GRIN Therapeutics announced a partnership with InformedDNA to provide free genetic counseling to US patients to determine gain-of-function/loss-of-function status and clinical trial eligibility. Recent published content covers pharmacogenomics in medication efficiency (September 2025), data security and privacy practices (May 2025), and a genetic counselor career webinar series (December 2025).